КОМПЛЕКСНЫЙ ПОДХОД В ИЗУЧЕНИИ ОСОБЕННОСТЕЙ НЕЙРОФИБРОМАТОЗА 1 ТИПА
https://doi.org/10.24060/2076-3093-2012-0-1-98-102
Аннотация
В обзоре литературы представлен анализ данных отечественных и зарубежных исследователей по изучению нейрофиброматоза 1 типа. Приведены основные особенности патогенеза, клиники и генетических основ заболевания. Обобщены современные данные о диагностике и лечении данной патологии.
Об авторах
Р. Н. МустафинРоссия
Мустафин Рустам Наилевич - заочный аспирант лаборатории молекулярной генетики человека.
450054, Республика Башкортостан, Уфа, пр. Октября, д. 71, тел. 8 (347) 235-60-88, e-mail: 021gen@mail.ru
М. А. Бермишева
Россия
Э. К. Хуснутдинова
Россия
Список литературы
1. Горбунова В.Н., Имянитов Е.Н., Ледащева Т.А. Молекулярная неврология. Часть III // Опухоли головного мозга, онкогены и антионкогены. – СПб.: «Интермедика», 2004. – С. 219-232.
2. Дрозд О.В., Бабенко О.В., Семячкина А.Н. и др. Разработка подходов к ДНК-диагностике нейрофиброматоза 1-го типа в России // Медицинская генетика. – 2005. – Т. 4. – №7. – С. 322-326.
3. Макурдумян Л.А. Нейрофиброматоз I типа. Проблемы диагностики и лечения // Лечащий врач. – 2001. – №10. – С. 59-61.
4. Шнайдер Н.А. Нейрофиброматоз 1-го типа: этиопатогенез, клиника, диагностика, прогноз // Международный неврологический журнал. – 2007. – №5. – С. 24-28.
5. Banerjee S., Byrd J.N., Gianino S.M. et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo // Cancer Res. – 2010. – №70(4). – Р. 1356-1366.
6. Bottillo I., Luca A., Schirinzi A. et al. Functional analysis of splicing mutations in exon 7 of NF1 gene // BMC Medical Genetics. – 2007. – №8. – P. 4-13.
7. Cunha K.G., Barboza E.P., Fonseca E.C. Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1 // J. Clin. Pathol. – 2003. – Vol. 56. – P. 758-763.
8. Donarum E.A., Halperin R.F., Stephan D.A. Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex // BMC Neurosci. – 2006. – №7. – P. 22-33.
9. Ebinger M., Senf L., Wachowski O. et al. No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood // Pediatric Hematology and Oncology. – 2005. – Vol. 22. - №1. – P. 83–87.
10. Feng-Chun Y., Ingram D.A., Chen S. et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for NF1+/mast cells // J. Clin. Invest. – 2003. – Vol. 112. №12. – P. 1851-1861.
11. Geller M., Ribeiro M.G. Serum IgE levels in neurofibromatosis 1 // Int. J. Immunogenet. – 2006. – Vol. 33. – №2. – P. 111-115.
12. Hawes J.J., Tuskan R.G., Reilly K.M. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. // Neurogenetics. – 2007. – №10. – P. 1007-1019.
13. Hiatt K., Ingram D., Huddlesto H. et al. Loss of the NF1 tumor suppressor gene decreases fas antigen expression in myeloid cells // American Journal of Pathology. – 2004. – Vol. 164. – №4. – P. 1471-1479.
14. Johannessen C.M., Reczek E.E., James M.F. The NF1 tumor suppressor critically regulates TSC2 and mTOR // Proc. Natl. Acad. Sci. USA. – 2005. – Vol. 102. – №24. – P. 8573-8578.
15. Kaufmann D., Muller R., Bartelt B. et al. Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene // Am. J. Hum. Genet. – 2001. – Vol. 69. – №6. – P. 1395-1400.
16. Kilic S., Tezcan I., Sanal O., Ersoy F. Common variable immunodeficiency in a patient with neurofibromatosis. // Pediatrics International. – 2001. – Vol. 43. – P. 691-693.
17. Kluwe L., Siebert R., Gesk S. et al. Screening 500 unselected eurofibromatosis 1 patients for deletions of the NF1 gene // Human Mutation. – 2004. – Vol. 23. – №2. – P. 111-116.
18. Kluwe L., Friedrich R.E., Korf B. et al. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas // Human Mutation. – 2002. – Vol. 19. – №3. – P. 309-315.
19. Kweh F., Zheng M., Kurenova E. et al. Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase // Mol. Carcinog. – 2009. - Vol. 48. – №11. – P. 1005-1017.
20. Lasater E.A., Li F., Bessler W.K., Estes M.L. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans // J. Clin. Invest. – 2010. – Vol. 120. – №3. – P. 859-870.
21. Lee P.R., Cohen J.E., Fields R.D. Immune system evasion by peripheral nerve sheath tumor // Neurosci. Lett. – 2006. – Vol. 397. – №1. – P. 126-129.
22. Luijten M., Wang Y., Smith B.T. et al. Mechanism of spreading of the highly related neurofibromatosis type 1 (NF1) pseudogenes on chromosomes 2, 14 and 22 // Eur. J. Hum. Genet. – 2000. – Vol. 8. – №3. – P. 209-214.
23. McDaniel A.S., Allen J.D., Park S.J. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/mast cells // Blood. – 2008. – Vol. 112. – №12. – P. 4646-4654.
24. Mukhopadhyay D., Anant S., Lee R.M. et al. С > U editing of Neurofibromatosis 1 mRNA Occurs in Tumors That Express Both the Type II Transcript and apobec-1, the Catalytic Subunit of the Apolipoproten B mRNA-Editing Enzyme // Am. J. Hum. Genet. – 2002. – Vol. 70. – P. 38-50.
25. MvGillicuddy L.T., Fromm J.A., Hollstein P.E. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis // Cancer Cell. – 2009. – Vol. 16. – №1. – P. 44-54.
26. Patrakitkomjorn S., Kobayashi D., Morikawa T. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2 // The Journal of Biological Chemistry. – 2008. – Vol. 283. – Р. 9399-9413.
27. Sangha N., Wu R., Kuick R. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations // Neoplasia. – 2008. – №10. – P. 1362-1372.
28. Schepper S., Maertens O., Callens T. et al. Somatic Mutation Analysis in NF1 Cafe au lait Spots Re- veals Two NF1 Hits in the Melanocytes // Journal of Investigative Dermatology. – 2008. – Vol. 128. – P. 1050-1053.
29. Stevenson D., Zhou H., Ashrafi S. et al. Double inactivation of NF1 in tibial pseudarthrosis // The American Journal of Human Genetics. – 2006. – Vol. 79. – №1. – P. 143-148.
30. Upadhyaya M., Huson S.M., Davies M. et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation // The American Journal of Human Genetics. – 2007. – Vol. 80. – P. 140-151.
31. Weiqi H., Horvath E., Eklund E. A. PU.1, interferon regulatory factor (IRF)2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells // The Journal of Biological Chemistry. – 2007. – Vol. 282. – P. 6629-6643.
32. Wimmer K. Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome // Wien. Med. Wochenschr. – 2005. – Vol. 155. – №11. – P. 273-280.
33. Yang G., Khalaf W., Locht L. et al. Transcriptional repression of the neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein // Molecular and cellular biology. – 2005. – Vol. 25. – №14. – P. 5869-5879.
34. Zhu C., Saberwal G., Lu Y. et al. The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1 // J. Biol. Chem. – 2004. – Vol. 279. – №49. – P. 50874-50885.
Рецензия
Для цитирования:
Мустафин Р.Н., Бермишева М.А., Хуснутдинова Э.К. КОМПЛЕКСНЫЙ ПОДХОД В ИЗУЧЕНИИ ОСОБЕННОСТЕЙ НЕЙРОФИБРОМАТОЗА 1 ТИПА. Креативная хирургия и онкология. 2012;(1):98-102. https://doi.org/10.24060/2076-3093-2012-0-1-98-102
For citation:
Mustafin R.N., Bermisheva M.A., Khusnutdinova E.K. A COMPREHENSIVE APPROACH TO THE STUDY OF PECULIAR PROPERTIES OF NEUROFIBROMATOSIS TYPE 1. Creative surgery and oncology. 2012;(1):98-102. (In Russ.) https://doi.org/10.24060/2076-3093-2012-0-1-98-102